{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:11:14Z","timestamp":1787800274755,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10157-025-02709-5","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:02:03Z","timestamp":1749027723000},"page":"1363-1372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term prognosis of pure membranous lupus nephritis: a comparison with proliferative lupus nephritis in Japan"],"prefix":"10.1007","volume":"29","author":[{"given":"Hidekazu","family":"Ikeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9490-8364","authenticated-orcid":false,"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2709_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"2709_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018;93:789\u201396.","journal-title":"Kidney Int"},{"key":"2709_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1191\/0961203305lu2062oa","volume":"14","author":"HA Austin","year":"2005","unstructured":"Austin HA, Illei GG. Membranous lupus nephritis. Lupus. 2005;14:65\u201371.","journal-title":"Lupus"},{"key":"2709_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","volume":"41","author":"G Moroni","year":"2012","unstructured":"Moroni G, Quaglini S, Gravellone L, et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum. 2012;41:642\u201351.","journal-title":"Semin Arthritis Rheum"},{"key":"2709_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3109\/14397595.2016.1158896","volume":"26","author":"H Ikeuchi","year":"2016","unstructured":"Ikeuchi H, Hiromura K, Kayakabe K, et al. Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III\/IV+V): a long-term observational study. Mod Rheumatol. 2016;26:908\u201313.","journal-title":"Mod Rheumatol"},{"key":"2709_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797\u2013808.","journal-title":"Arthritis Care Res"},{"key":"2709_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mej\u00eda-Vilet JM, Floege J. Kidney disease: improving global outcomes lupus nephritis Work G. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105:S1\u201369.","journal-title":"Kidney Int"},{"key":"2709_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0961203309106602","volume":"18","author":"CC Mok","year":"2009","unstructured":"Mok CC, Ying KY, Yim CW, et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18:1091\u20135.","journal-title":"Lupus"},{"key":"2709_CR10","doi-asserted-by":"publisher","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","volume":"7","author":"G Moroni","year":"2020","unstructured":"Moroni G, Ponticelli C. Secondary membranous nephropathy. A narrative review. Front Med (Lausanne). 2020;7:611317.","journal-title":"Front Med (Lausanne)"},{"key":"2709_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrneph.2009.14","volume":"5","author":"CC Mok","year":"2009","unstructured":"Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol. 2009;5:212\u201320.","journal-title":"Nat Rev Nephrol"},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68:1432\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"2709_CR13","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","volume":"27","author":"DY Yap","year":"2012","unstructured":"Yap DY, Tang CS, Ma MK, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"2709_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1053\/j.ackd.2019.08.009","volume":"26","author":"S Almaani","year":"2019","unstructured":"Almaani S, Parikh SV. Membranous Lupus Nephritis: a clinical review. Adv Chronic Kidney Dis. 2019;26:393\u2013403.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2709_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10157-022-02232-x","volume":"26","author":"H Ikeuchi","year":"2022","unstructured":"Ikeuchi H, Sugiyama H, Sato H, et al. A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022;26:898\u2013908.","journal-title":"Clin Exp Nephrol"},{"key":"2709_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345.","journal-title":"Ann Rheum Dis"},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"2709_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/nep.12863","volume":"22","author":"K Hiromura","year":"2017","unstructured":"Hiromura K, Ikeuchi H, Kayakabe K, et al. Clinical and histological features of lupus nephritis in Japan: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR). Nephrology. 2017;22:885\u201391.","journal-title":"Nephrology"},{"key":"2709_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2709_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.809533","volume":"9","author":"E Kapsia","year":"2022","unstructured":"Kapsia E, Marinaki S, Michelakis I, et al. New insights into an overlooked entity: long-term outcomes of membranous lupus nephritis from a single institution inception cohort. Front Med (Lausanne). 2022;9: 809533.","journal-title":"Front Med (Lausanne)"},{"key":"2709_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/09612033231225345","volume":"33","author":"J Hu","year":"2024","unstructured":"Hu J, Zhu M, Wang J, et al. The clinicopathological features and renal prognostic factors in pure membranous lupus nephritis-a large series cohort study from China. Lupus. 2024;33:192\u2013200.","journal-title":"Lupus"},{"key":"2709_CR23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/rheumatology\/keaa103","volume":"59","author":"F Farinha","year":"2020","unstructured":"Farinha F, Pepper RJ, Oliveira DG, et al. Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. Rheumatology (Oxford). 2020;59:3314\u201323.","journal-title":"Rheumatology (Oxford)"},{"key":"2709_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae436","author":"F Kharouf","year":"2024","unstructured":"Kharouf F, Li Q, Whittall Garcia LP, et al. Short and long-term outcomes of patients with pure membranous lupus nephritis compared to patients with proliferative disease. Rheumatology. 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae436.","journal-title":"Rheumatology"},{"key":"2709_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.reuma.2017.04.005","volume":"15","author":"L Silva-Fernandez","year":"2019","unstructured":"Silva-Fernandez L, Oton T, Askanase A, et al. Pure membranous lupus nephritis: description of a cohort of 150 patients and review of the literature. Reumatol Clin (Engl Ed). 2019;15:34\u201342.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2709_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1681\/ASN.2020081181","volume":"32","author":"A Ravindran","year":"2021","unstructured":"Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol. 2021;32:695\u2013706.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02709-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:38:44Z","timestamp":1758789524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02709-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02709-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Hiromura has received consultancy fees from Otsuka Pharmaceutical, GlaxoSmithKline, research support from Chugai Pharmaceutical, and speaker fees from Astellas Pharma, AstraZeneca, Asahi Kasei Pharma, GlaxoSmithKline, Kissei Pharmaceutical, and Otsuka Pharmaceutical. S. Maruyama has received consultancy fees from Otsuka Pharmaceutical, speaker fees from Astellas Pharma, AstraZeneca, joint research expenses from Chugai Pharmaceutical, Zenyaku Kogyo, and scholarship donation from Otsuka Pharmaceutical. H Ikeuchi has received speaker fees from Astellas Pharma, AstraZeneca, Glaxo Smith K line. Y Imai, H Sugiyama, H Sato, and H. Yokoyama have no COI to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective cohort study followed the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Japanese Society of Nephrology (Reference number: 111) and the Ethics Committee of Gunma University Graduate School of Medicine [Reference number: IRB2023-53(2124)].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients were provided with the opportunity to opt out of participating in this study, and all study information was provided on the institution\u2019s home page.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}